Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care

Journal of Rheumatology

Volumn 31, Issue 6, 2004, Pages 1143-1151

  Wolfe, Frederick ^a   Zhao, Sean ^b   Reynolds, Matthew ^c   Pettitt, Dan ^d  

^a ARTHRITIS RESEARCH CENTER FOUNDATION   (United States)

^b Pharmacia Global Health Outcomes   (United States)

^c PFIZER INC   (United States)

^d Pfizer Outcomes Research   (United States)

Author keywords

Adverse events; Cyclooxygenase 2; Edema; Hypertension; Nonsteroidal antiinflammatory drug

Indexed keywords

ACETYLSALICYLIC ACID; ARTHROTEC; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; FENOPROFEN; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; MECLOFENAMIC ACID; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPRAZINE; PIROXICAM; PLACEBO; ROFECOXIB; SALSALATE; SULINDAC; TOLMETIN;

ADULT; AGED; ANAMNESIS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG UTILIZATION; EVALUATION; FEMALE; HEART DISEASE; HUMAN; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; OUTCOMES RESEARCH; PATIENT CARE; PERIPHERAL EDEMA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SELF REPORT;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; BLOOD PRESSURE; CYCLOOXYGENASE 2; EDEMA; FEMALE; HUMANS; HYPERTENSION; ISOENZYMES; LACTONES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; OSTEOARTHRITIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SULFONAMIDES; SULFONES; TREATMENT OUTCOME;

EID: 2642529302     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995;25:305-13.
2. Wolfe F. Hypertension among patients with rheumatoid and osteoarthritis participating in the National Data Bank for Rheumatic Diseases. J Rheumatol 2002.
3. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996;275:1557-62.
4. Grundy SM, Balady GJ, Criqui MH, et al. Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. Circulation 1998;97:1876-87.
5. Moser M, Hebert P, Hennekens CH. An overview of the meta-analyses of the hypertension treatment trials. Arch Intern Med 1991;151:1277-9.
6. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38.
7. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993;153:477-84.
8. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994;121:289-300.
9. Appel GB. COX-2 inhibitors and the kidney. Clin Exp Rheumatol 2001;19:S37-40.
10. Sundy JS. COX-2 inhibitors in rheumatoid arthritis. Curr Rheumatol Rep 2001;3:86-91.
11. Zhao SZ, Reynolds MW, Lejkowith J, Whelton A, Arellano FM. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib. Clin Ther 2001;23:1478-91.
12. Whelton A, Maurath CJ, Verburg KM, Geis GS. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther 2000;7:159-75.
13. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001;8:85-95.
14. Whelton A, White WB, Bello AE, Puma JA, Fort JG, The Success-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002;90:959-63.
15. Wolfe F, Flowers N, Anderson J. The National Rheumatic Disease Data Bank: case mix and severity characteristics of patients in rheumatological practice [abstract]. Arthritis Rheum 1998;41 Suppl:S132.
16. Fries JE, Spitz PW, Young DY. The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93.
17. Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
18. Assessment in rheumatoid arthritis. Lancet 1968;2:1379-81.
19. Meenan RF, Gertman PM, Mason JH, Dunaif R. The Arthritis Impact Measurement Scales. Arthritis Rheum 1982;25:1048-53.
20. Meenan RF. The AIMS approach to health status measurement: conceptual background and measurement properties. J Rheumatol 1982;9:785-8.
21. Wolfe F, Hawley DJ. The relationship between clinical activity and depression in rheumatoid arthritis. J Rheumatol 1993;20:2032-7.
22. Hawley DJ, Wolfe F. Anxiety and depression in patients with rheumatoid arthritis: a prospective study of 400 patients. J Rheumatol 1988;15:932-41.
23. Ware JE, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36). 1. Conceptual framework and item selection. Med Care 1992;30:473-83.
24. Wolfe F. Determinants of WOMAC function, pain and stiffness scores: evidence for the role of low back pain, symptom counts, fatigue and depression in osteoarthritis, rheumatoid arthritis and fibromyalgia. Rheumatology Oxford 1999;38:355-61.
25. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40.
26. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: Validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997;36:551-9.
27. Wolfe F, Hawley DJ. Measurement of the quality of life in rheumatic disorders using the EuroQol. Br J Rheumatol 1997;36:786-93.
28. Stata Corporation. Stata statistical software: Release 7.0. College Station, TX: Stata Corp.; 2001.
29. Wolfe F, Flowers N, Burke TA, Arguelles LM, Pettitt D. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 2002;29:1015-22.
30. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8.
31. Tannenbaum H, Davis P, Russell AS, et al. An evidence-based approach to prescribing NSAIDs in musculoskeletal disease: a Canadian consensus. Canadian NSAID Consensus Participants. CMAJ 1996;155:77-88.
32. Radack KL, Deck CC, Bloomfield SS. Ibuprofen interferes with the efficacy of antihypertensive drugs. A randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen. Ann Intern Med 1987;107:628-35.